{"nctId":"NCT03961529","briefTitle":"Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis","startDateStruct":{"date":"2019-05-14","type":"ACTUAL"},"conditions":["Atopic Dermatitis"],"count":366,"armGroups":[{"label":"0.3% OPA-15406 ointment","type":"EXPERIMENTAL","interventionNames":["Drug: 0.3% OPA-15406 ointment"]},{"label":"1% OPA-15406 ointment","type":"EXPERIMENTAL","interventionNames":["Drug: 1% OPA-15406 ointment"]}],"interventions":[{"name":"0.3% OPA-15406 ointment","otherNames":[]},{"name":"1% OPA-15406 ointment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age: At least 2 years (at time of obtaining informed consent)\n* Diagnosis of AD based on the Japanese Dermatological Association's criteria\n* Atopic dermatitis affecting ≥5% of body surface area (BSA, excluding scalp) at the screening and baseline examinations\n\nExclusion Criteria:\n\n\\- Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)","description":"The number of subjects were calculated regarding adverse events occurring after IMP administration (=TEAEs).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder Rate of Investigator's Global Assessment (IGA)","description":"The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 52.\n\nIncidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.94","spread":null},{"groupId":"OG001","value":"52.78","spread":null},{"groupId":"OG002","value":"51.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder Rate of Eczema Area and Severity Index 75 (EASI 75)","description":"The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD. The investigator or sub investigator scored the severity (0-3 points) and affected body surface area (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs).\n\nEASI 75 is defined as the rate of subjects whose EASI score has improved at least 75% from baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.42","spread":null},{"groupId":"OG001","value":"77.08","spread":null},{"groupId":"OG002","value":"64.29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":166},"commonTop":["Nasopharyngitis","Dermatitis atopic","Impetigo","Influenza","Conjunctivitis allergic"]}}}